Recent Updates
Recently added Catalysts

Serogroup B meningococcal Vaccine lot 1

Phase 3

Serogroup B Meningococcal Meningitis | Monoclonal antibody | Infectious Disease |Novartis AG|Last Updated: Oct 10, 2017

Target and mechanism

ModalityMonoclonal antibody

Also known as Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1)

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLEDDMC
Total Trials1
Total Enrollment3,630

FDA Designations

No designations recorded

Clinical trial landscape

Serogroup B meningococcal Vaccine lot 1 · 1 trial · 1 indication

Phase 3 1
NCT00657709Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy InfantsSerogroup B Meningococcal Meningitis
COMPLETED3,630 Analytics
PHASE3COMPLETED
Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
Serogroup B Meningococcal MeningitisUnlock trial analytics

Study Endpoints

Primary Endpoints

The Geometric Mean Human Serum Bactericidal Activity (hSBA) Titers After Three Doses of rMenB+OMV NZ Vaccination
one month after the third vaccination

The hSBA antibody titer responses, one month after receiving the third vaccination of rMenB+OMV NZ vaccination, are reported as geometric mean titers (GMTs).

The Percentages of Subjects With hSBA Titer ≥1:5 After Receiving Three Doses of rMenB+OMV Vaccination (3 Lots Combined)
one month after the third vaccination

The immunogenicity was assessed in terms of the percentages of subjects who had received the three doses of rMenB+OMV NZ (3 lots combined) given concomitantly with routine infant vaccinations and percentages of subjects who received only the routine infant vaccinations as measured by hSBA titer ≥1:5 following rMenB+OMV NZ vaccinations one month after the third vaccination is reported.

Secondary Endpoints

The Percentages of Subjects With hSBA Titer ≥1:5 After Receiving Three Doses of rMenB+OMV Vaccination (From 3 Lots)
1 month after the third vaccination
Geometric Mean Human Serum Bactericidal Activity Titers After the Routine Vaccination Without rMenB OMV NZ
1 Month after the third vaccination
Geometric Mean Concentrations After Three Doses of rMenB+OMV NZ Vaccination (Against the 287-953 Antigen)
1 month after third vaccination
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposePREVENTION

Treatment Arms

ArmTypeDescription
rMenB Lot1EXPERIMENTALSubjects received one injection of rMenB+OMV NZ (Lot 1) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.
rMenB Lot2EXPERIMENTALSubjects received one injection of rMenB+OMV NZ (Lot 2) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.
rMenB Lot3EXPERIMENTALSubjects received one injection of rMenB+OMV NZ (Lot 3) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.
RoutineACTIVE_COMPARATORSubjects received the routinely administered infant vaccines at 2, 4, 6 months of age.
MenC + RoutineACTIVE_COMPARATORSubjects received the routinely administered infant vaccines and Men C vaccine at 2, 4 and 6 months of age.

Interventions

NameTypeDescription
Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1)BIOLOGICALOne dose of rMenB Lot concomitantly with the routinely administered infant vaccines
Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2)BIOLOGICALOne dose of rMenB concomitantly with the routinely administered infant vaccines
Serogroup B meningococcal Vaccine lot 3 (rMenB Lot 3)BIOLOGICALOne dose of rMenB concomitantly with the routinely administered infant vaccines
Infanrix HexaBIOLOGICALRoutine vaccination
MenjugateBIOLOGICALOne dose of the routinely administered infant vaccines + MenC vaccine
PrevenarBIOLOGICALRoutine vaccination
Unlock Study Design Details

Eligibility Criteria

Age Range55 Days to 89 Days
SexALL
Healthy VolunteersYes
Study Sites66

Inclusion Criteria: * Healthy 2-month old infants (55-89 days, inclusive) Exclusion Criteria: * Prior vaccination with routine infant vaccines (Diphtheria, Tetanus, Pertussis, Polio, Haemophilus influenzae type b (Hib), and Pneumococcal antigens) * Previous ascertained or suspected disease caused...

Countries:AustriaCzechiaFinlandGermanyItaly
Unlock Eligibility Criteria